These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30146169)

  • 21. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.
    Choi JH; Banks AS; Kamenecka TM; Busby SA; Chalmers MJ; Kumar N; Kuruvilla DS; Shin Y; He Y; Bruning JB; Marciano DP; Cameron MD; Laznik D; Jurczak MJ; Schürer SC; Vidović D; Shulman GI; Spiegelman BM; Griffin PR
    Nature; 2011 Sep; 477(7365):477-81. PubMed ID: 21892191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural Basis for the Regulation of PPARγ Activity by Imatinib.
    Jang JY; Kim HJ; Han BW
    Molecules; 2019 Oct; 24(19):. PubMed ID: 31581474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain.
    Amato AA; Rajagopalan S; Lin JZ; Carvalho BM; Figueira AC; Lu J; Ayers SD; Mottin M; Silveira RL; Souza PC; Mourão RH; Saad MJ; Togashi M; Simeoni LA; Abdalla DS; Skaf MS; Polikparpov I; Lima MC; Galdino SL; Brennan RG; Baxter JD; Pitta IR; Webb P; Phillips KJ; Neves FA
    J Biol Chem; 2012 Aug; 287(33):28169-79. PubMed ID: 22584573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PPARγ helix 12 exhibits an antagonist conformation.
    Fratev F
    Phys Chem Chem Phys; 2016 Apr; 18(13):9272-80. PubMed ID: 26975214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural and Dynamical Insight into PPARγ Antagonism: In Silico Study of the Ligand-Receptor Interactions of Non-Covalent Antagonists.
    Fratev F; Tsakovska I; Al Sharif M; Mihaylova E; Pajeva I
    Int J Mol Sci; 2015 Jul; 16(7):15405-24. PubMed ID: 26184155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The nuclear receptor PPARγ individually responds to serotonin- and fatty acid-metabolites.
    Waku T; Shiraki T; Oyama T; Maebara K; Nakamori R; Morikawa K
    EMBO J; 2010 Oct; 29(19):3395-407. PubMed ID: 20717101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.
    Gilardi F; Giudici M; Mitro N; Maschi O; Guerrini U; Rando G; Maggi A; Cermenati G; Laghezza A; Loiodice F; Pochetti G; Lavecchia A; Caruso D; De Fabiani E; Bamberg K; Crestani M
    J Biol Chem; 2014 Mar; 289(10):6908-6920. PubMed ID: 24451380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPARγ phosphorylation.
    Jang JY; Kim H; Kim HJ; Suh SW; Park SB; Han BW
    Sci Rep; 2019 Aug; 9(1):11168. PubMed ID: 31371757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Magnolol dimer-derived fragments as PPARγ-selective probes.
    Dreier D; Resetar M; Temml V; Rycek L; Kratena N; Schnürch M; Schuster D; Dirsch VM; Mihovilovic MD
    Org Biomol Chem; 2018 Oct; 16(38):7019-7028. PubMed ID: 30232493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural basis for PPARγ transactivation by endocrine-disrupting organotin compounds.
    Harada S; Hiromori Y; Nakamura S; Kawahara K; Fukakusa S; Maruno T; Noda M; Uchiyama S; Fukui K; Nishikawa J; Nagase H; Kobayashi Y; Yoshida T; Ohkubo T; Nakanishi T
    Sci Rep; 2015 Feb; 5():8520. PubMed ID: 25687586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Honokiol: a non-adipogenic PPARγ agonist from nature.
    Atanasov AG; Wang JN; Gu SP; Bu J; Kramer MP; Baumgartner L; Fakhrudin N; Ladurner A; Malainer C; Vuorinen A; Noha SM; Schwaiger S; Rollinger JM; Schuster D; Stuppner H; Dirsch VM; Heiss EH
    Biochim Biophys Acta; 2013 Oct; 1830(10):4813-9. PubMed ID: 23811337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ.
    Jang JY; Bae H; Lee YJ; Choi YI; Kim HJ; Park SB; Suh SW; Kim SW; Han BW
    Sci Rep; 2018 Jan; 8(1):31. PubMed ID: 29311579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydrogen/deuterium exchange reveals distinct agonist/partial agonist receptor dynamics within vitamin D receptor/retinoid X receptor heterodimer.
    Zhang J; Chalmers MJ; Stayrook KR; Burris LL; Garcia-Ordonez RD; Pascal BD; Burris TP; Dodge JA; Griffin PR
    Structure; 2010 Oct; 18(10):1332-41. PubMed ID: 20947021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 3-phosphoinositide-dependent protein kinase-1 activates the peroxisome proliferator-activated receptor-gamma and promotes adipocyte differentiation.
    Yin Y; Yuan H; Wang C; Pattabiraman N; Rao M; Pestell RG; Glazer RI
    Mol Endocrinol; 2006 Feb; 20(2):268-78. PubMed ID: 16150867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unique Interactome Network Signatures for Peroxisome Proliferator-activated Receptor Gamma (PPARγ) Modulation by Functional Selective Ligands.
    Lam VQ; Zheng J; Griffin PR
    Mol Cell Proteomics; 2017 Dec; 16(12):2098-2110. PubMed ID: 28972081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PPARγ non-covalent antagonists exhibit mutable binding modes with a similar free energy of binding: a case study.
    Fratev F
    J Biomol Struct Dyn; 2017 Feb; 35(3):476-485. PubMed ID: 26872742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conformational analysis of g protein-coupled receptor signaling by hydrogen/deuterium exchange mass spectrometry.
    Li S; Lee SY; Chung KY
    Methods Enzymol; 2015; 557():261-78. PubMed ID: 25950969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cooperative cobinding of synthetic and natural ligands to the nuclear receptor PPARγ.
    Shang J; Brust R; Mosure SA; Bass J; Munoz-Tello P; Lin H; Hughes TS; Tang M; Ge Q; Kamenekca TM; Kojetin DJ
    Elife; 2018 Dec; 7():. PubMed ID: 30575522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding.
    Elbrecht A; Chen Y; Adams A; Berger J; Griffin P; Klatt T; Zhang B; Menke J; Zhou G; Smith RG; Moller DE
    J Biol Chem; 1999 Mar; 274(12):7913-22. PubMed ID: 10075686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) γ activators and pan-PPAR partial agonists.
    Liberato MV; Nascimento AS; Ayers SD; Lin JZ; Cvoro A; Silveira RL; Martínez L; Souza PC; Saidemberg D; Deng T; Amato AA; Togashi M; Hsueh WA; Phillips K; Palma MS; Neves FA; Skaf MS; Webb P; Polikarpov I
    PLoS One; 2012; 7(5):e36297. PubMed ID: 22649490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.